Tag: Gynecological Cancer

New discovery could overcome immune therapy failure in ovarian cancer

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment. Doctors may be able to use the findings to overcome this treatment failure and save the lives of thousands of women every year. The new discovery, from the lab… Continue reading New discovery could overcome immune therapy failure in ovarian cancer

Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer

Abstract Background The addition of immune checkpoint inhibitors to standard-of-care chemoradiation (CRT) is established as the new standard of care in high-risk, locally advanced cervical cancer. However, the optimal sequencing of therapies is unknown. Defining safety and feasibility of the combination was a primary objective of this study examining concurrent versus sequential schedules. Methods Pembrolizumab was given… Continue reading Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer

Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer

Abstract Background The addition of immune checkpoint inhibitors to standard-of-care chemoradiation (CRT) is established as the new standard of care in high-risk, locally advanced cervical cancer. However, the optimal sequencing of therapies is unknown. Defining safety and feasibility of the combination was a primary objective of this study examining concurrent versus sequential schedules. Methods Pembrolizumab was given… Continue reading Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer

Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III–IVa cervical cancer: is the ENGOT‐cx11/GOG‐3047/KEYNOTE‐A18 trial practice changing?

Abstract At the second interim analysis, the ENGOT-cx11/GOG-3047/KEYNOTE-A18 demonstrated an overall survival (OS) benefit after 36 months in stage III–IVa cervical cancer patients treated with chemoradiotherapy and concurrent pembrolizumab followed by 90 weeks of pembrolizumab as compared to placebo (82.6% vs. 74.8%, hazard ratio for death, 0.67 [confidence interval, 0.50–0.90]). Only 51 of 193 progressing… Continue reading Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III–IVa cervical cancer: is the ENGOT‐cx11/GOG‐3047/KEYNOTE‐A18 trial practice changing?

An Extremely Successful Vaccine Story

by Gertrud U. Rey One of the most noteworthy advances in biomedical science is the vaccine for human papillomavirus (HPV). It has significantly changed the diagnostic and prognostic landscape in the field of cervical cancer. Cervical cancer is the fourth most common cancer in women globally, and it is a particular problem in low-income countries… Continue reading An Extremely Successful Vaccine Story

Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III–IVa cervical cancer: is the ENGOT‐cx11/GOG‐3047/KEYNOTE‐A18 trial practice changing?

Abstract At the second interim analysis, the ENGOT-cx11/GOG-3047/KEYNOTE-A18 demonstrated an overall survival (OS) benefit after 36 months in stage III–IVa cervical cancer patients treated with chemoradiotherapy and concurrent pembrolizumab followed by 90 weeks of pembrolizumab as compared to placebo (82.6% vs. 74.8%, hazard ratio for death, 0.67 [confidence interval, 0.50–0.90]). Only 51 of 193 progressing… Continue reading Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III–IVa cervical cancer: is the ENGOT‐cx11/GOG‐3047/KEYNOTE‐A18 trial practice changing?